Advertisement
Canada markets closed
  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • DOW

    39,806.77
    -196.82 (-0.49%)
     
  • CAD/USD

    0.7337
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    79.72
    -0.08 (-0.10%)
     
  • Bitcoin CAD

    96,767.12
    +6,604.13 (+7.32%)
     
  • CMC Crypto 200

    1,509.86
    +155.44 (+11.47%)
     
  • GOLD FUTURES

    2,434.80
    -3.70 (-0.15%)
     
  • RUSSELL 2000

    2,102.50
    +6.78 (+0.32%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • NASDAQ

    16,794.88
    +108.91 (+0.65%)
     
  • VOLATILITY

    12.15
    +0.16 (+1.33%)
     
  • FTSE

    8,424.20
    +3.94 (+0.05%)
     
  • NIKKEI 225

    39,166.21
    +96.53 (+0.25%)
     
  • CAD/EUR

    0.6754
    -0.0002 (-0.03%)
     

Herbalife (HLF) Q1 Earnings Report Preview: What To Look For

HLF Cover Image
Herbalife (HLF) Q1 Earnings Report Preview: What To Look For

Health and wellness products company Herbalife (NYSE:HLF) will be announcing earnings results tomorrow after market close. Here's what investors should know.

Herbalife beat analysts' revenue expectations by 2.2% last quarter, reporting revenues of $1.22 billion, up 2.9% year on year. It was a weak quarter for the company, with a miss of analysts' EPS  estimates.

Is Herbalife a buy or sell going into earnings? Read our full analysis here, it's free.

This quarter, analysts are expecting Herbalife's revenue to grow 1.1% year on year to $1.27 billion, a reversal from the 6.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.37 per share.

Herbalife Total Revenue
Herbalife Total Revenue

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Herbalife has missed Wall Street's revenue estimates twice over the last two years.

ADVERTISEMENT

Looking at Herbalife's peers in the consumer staples segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Medifast's revenues decreased 49.9% year on year, meeting analysts' expectations, and Colgate-Palmolive reported revenues up 6.2%, topping estimates by 2.1%. Colgate-Palmolive traded up 1.3% following the results.

Read our full analysis of Medifast's results here and Colgate-Palmolive's results here.

Stocks, especially growth stocks where cash flows further in the future are more important to the story, had a good end of 2023. But the beginning of 2024 has seen more volatile stock performance thanks to mixed inflation data, and while some of the consumer staples stocks have fared somewhat better, they have not been spared, with share prices down 3.6% on average over the last month. Herbalife's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $11.9 (compared to the current share price of $9.06).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.